Abstract
Bloodstream infections (BSIs) cause >500,000 infections and >80,000 deaths per year in North America. The length of time between the onset of symptoms and administration of appropriate antimicrobials is directly linked to mortality rates. It currently takes 2-5 days to identify BSI pathogens and measure their susceptibility to antimicrobials – a timeline that directly contributes to preventable deaths. To address this, we developed a rapid metabolic preference assay (MPA) that uses the pattern of metabolic fluxes observed in ex-vivo microbial cultures to identify common pathogens and determine their antimicrobial susceptibility profiles. In a head-to-head race with a leading platform (VITEK 2) used in diagnostic laboratories, MPA decreased testing timelines from 40 hours to under 20. If put into practice, this assay could reduce septic shock mortality and reduce the use of broad spectrum antibiotics.
One Sentence Summary Metabolomics enables rapid diagnosis of BSIs.
Competing Interest Statement
Drs. Lewis and Dr. Rydzak are authors on a patent relating to the use of LC-MS for detecting blood stream infections. No other competing interests declared.
Funding Statement
This work was supported by Genome Canada (10019200), Genome Alberta (10021232), Canadian Institute of Health Research (10020019), Calgary Laboratory Services (RS-16802), and the University of Calgary (Biomedical Engineering 10011121). I.A.L and R.P. are supported by an Alberta Innovates Translational Health Chair (10010625). T.R. is supported by an Eyes High Postdoctoral Fellowship from the University of Calgary (10011121). Metabolomics data were acquired by R.A.G. and R.Z. at the Calgary Metabolomics Research Facility, which is supported by the International Microbiome Centre and the Canada Foundation for Innovation (CFI-JELF 34986).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by the University of Calgary's Conjoint Health Research Ethics Board under certificate # REB17-1525.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is included in supplemental files.
